Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer, Inc.    PFE


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Second Medical Use Inventions: "Everything Old Is New Again"

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 10:10am EDT

In the current COVID-19 environment, much of the innovation that we will require to tackle this pandemic will be borrowed from innovations of the past. As the great Australian musician Peter Allen once sang:

"Don't throw the past away

You might need it some rainy day

Dreams can come true again

When everything old is new again"

As the number of infections surpasses 3 million worldwide with over 200,000 deaths spanning over 200 countries, the social and economic imperative for new treatments continues to escalate.

While researchers worldwide are dedicated to the important work of finding a new vaccine for COVID-19, it is important to remember that pharmaceutical innovation does not necessarily mean discovering a completely new drug. Innovation lies in many places, including incremental improvements to known drugs products and treatment regimes, as well as the discovery of new uses for known drugs - so-called "second medical uses."

Second medical uses can provide distinct public health benefits in a relatively expedient fashion by reducing the research, development and regulatory burdens associated with bringing a new drug to market.

Second medical use patents

Not only could second medical uses represent the first line of treatment for COVID-19, they also offer significant commercial benefits when protected via patents. While second medical use claims come in a variety of forms, including method of medical treatment and Swiss-style claims, it is possible to obtain a patent for a second (or subsequent) medical use in one form or another in a number of major jurisdictions, including US, Europe, Japan, Israel, China, Australia and New Zealand, where a new and non-obvious therapeutic indication is discovered for a known active pharmaceutical ingredient (API).

Some well-known examples of second medical use patents include those relating to Pfizer's blockbuster drugs Viagra® (sildenafil) and Lyrica® (pregabalin). Sildenafil was first developed for the treatment of cardiovascular disease, but was later discovered to treat erectile dysfunction and marketed as Viagra®. Similarly, pregabalin was first developed for the treatment of epilepsy, and later discovered to treat pain and marketed as the drug Lyrica®. Both APIs were protected from a very early stage of development by patents. However, Pfizer was also able to obtain, defend and enforce patents directed to the newly discovered second medical uses in a number of jurisdictions, which provided protection for these specific uses long after the patents for the original APIs expired.

Sales of Viagra® for erectile dysfunction were estimated at US$1.6 billion in 2016 (before losing market exclusivity in the US in 2017), while 2019 sales of Lyrica® for the treatment of pain were estimated at US$3.3 billion. These examples, among many others, and the extensive resources poured into litigation on the relevant second medical use patents, highlight their commercial importance.

Benefits for research organisations, biotechs and SMEs

Second medical use patents are not just the domain of big pharma, they can also provide commercial advantages and opportunities for research organisations, biotechs and SMEs:

  • the time, cost and resources associated with the R&D of a new drug product is significantly reduced;
  • the safety hurdles associated with obtaining regulatory approval can also be significantly reduced, particularly where original drug formulation is unaltered;
  • patents can help to attract investors to fund vital research;
  • patents can lead to opportunities for research organisations and SMEs to collaborate/partner with big pharma; and
  • patents can form the basis for licenses or other agreements with third parties, providing a return on investment.
  • Where a patent already exists for the API, a second medical use patent may help to extend the lifecycle of an existing patent portfolio. This may be particularly valuable to originators and could lead to favourable partnership agreements, including licenses and acquisitions, for the patentee.

    Current COVID-19 therapies

    There is currently no proven treatment for COVID-19, although a number of vaccines are in various stages of development. Additionally, several known APIs have shown promising activity against SARS-CoV-2, but up to now controlled clinical trial results are limited. These APIs include chloroquine and hydroxychloroquine (used in the treatment of malaria), and the combination drug lopinavir/ritonavir (used in the treatment of HIV):


    Other compounds have also shown promise in the treatment of COVID-19. However, where such compounds have not previously gained regulatory approval, it may be some time before they can be established as safe and efficacious in humans. For example, remdesivir has been touted as the most promising candidate for the treatment of COVID-19, but recent reports suggest that the first Phase 3 clinical trials of this drug were terminated early due to adverse side-effects, so it remains to be seen whether it is a viable treatment option.

    These and other results from around the world indicate that further investigation into the repurposing of known drugs could be the key to a first-line treatment against COVID-19 and possible future coronavirus outbreaks. In the end, innovation will prevail and see us into a new era. Comfort should be taken in knowing that not everything will drastically change. Peter Allen was well aware of this too when he sang:

    "Dancin' at church, Long Island jazzy parties

    Waiter bring us some more Baccardi

    We'll order now what they ordered then

    'Cause everything old is new again."

    Originally published 28th April 2020

    The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

    Mr Mathew Lucas
    Davies Collison Cave
    1 Nicholson Street
    Tel: 39254 2777
    Fax: 39254 2770
    E-mail: RBattaglia@davies.com.au
    URL: www.davies.com.au

    © Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    Latest news on PFIZER, INC.
    06/04GLOBAL MARKETS LIVE: LVMH buyer’s remorse, Amazon faces lawsuit…
    06/03PFIZER : Complete Results from Second Pivotal Monotherapy Study of Abrocitinib P..
    06/03Health Care Down Amid Cyclical Bias -- Health Care Roundup
    06/03MAYNE PHARMA : Toni Nesci named head of Mayne Contract Services and New Website ..
    06/03Investors Channel Over $150 Billion Into Coronavirus Bonds
    06/02Health Care Up, But Not By Much, Amid Cyclical Bias -- Health Care Roundup
    06/02PFIZER : Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ..
    06/02PFIZER : to Invest $500 Million in Biotech Companies
    06/02PFIZER : Establishes New Program to Support Continued Biotechnology Innovation
    06/01Stocks rise on recovery hopes
    More news
    Financials (USD)
    Sales 2020 46 506 M - -
    Net income 2020 11 419 M - -
    Net Debt 2020 33 950 M - -
    P/E ratio 2020 18,2x
    Yield 2020 4,20%
    Capitalization 200 B 200 B -
    EV / Sales 2019
    EV / Sales 2020 5,03x
    Nbr of Employees 88 300
    Free-Float 59,1%
    Chart PFIZER, INC.
    Duration : Period :
    Pfizer, Inc. Technical Analysis Chart | MarketScreener
    Full-screen chart
    Technical analysis trends PFIZER, INC.
    Short TermMid-TermLong Term
    Income Statement Evolution
    Mean consensus OUTPERFORM
    Number of Analysts 17
    Average target price 41,28 $
    Last Close Price 36,01 $
    Spread / Highest target 52,7%
    Spread / Average Target 14,6%
    Spread / Lowest Target -2,80%
    EPS Revisions
    Albert Bourla Chairman, Chief Executive & Operating Officer
    Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
    Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
    W. Don Cornwell Independent Director
    Suzanne Nora Johnson Independent Director
    Sector and Competitors
    1st jan.Capitalization (M$)
    PFIZER, INC.-8.09%200 030
    JOHNSON & JOHNSON0.59%386 574
    ROCHE HOLDING AG5.97%296 065
    MERCK & CO., INC.-10.34%205 840
    NOVARTIS AG-11.02%188 340
    ABBVIE INC.5.08%163 968